Patient digital twin market seen reaching $13.28B by 2030

The patient digital twin platform market is projected to grow from $4.06 billion in 2026 to $13.28 billion by 2030, according to The Business Research Company. The report points to personalized medicine, EHR adoption, and AI-powered healthcare as the main forces behind the expansion.

Why it matters: - Patient digital twin platforms are moving from a niche concept to a core healthcare analytics tool. - The technology could help clinicians predict disease progression, test treatment options, and tailor care using patient-specific data. - The market’s growth signals rising demand for predictive and preventive care across health systems and life sciences.

What happened: - The Business Research Company released its Patient Digital Twin Platform Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report projects the market will grow from $3.01 billion in 2025 to $4.06 billion in 2026. - The report forecasts the market will reach $13.28 billion by 2030, implying a 34.5% CAGR. - In 2025, Asia-Pacific was the largest regional market and is expected to be the fastest-growing through the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Patient digital twin platforms create a virtual model of an individual by combining clinical records, medical imaging, wearable sensor data and biological information. - The platforms use artificial intelligence, simulation models and analytics to mirror physiology and forecast disease progression and treatment response. - The report cites personalized medicine as a major growth driver. - Personalized medicine tailors treatment and prevention using genetic profile, lifestyle, environmental influences and health data. - The report says genomics advances are improving genetic sequencing, helping providers identify genetic variations, assess disease risk and design targeted therapies. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - The report also points to wider EHR adoption as a growth driver. - EHRs support data sharing across providers and improve clinical decision-making and care coordination. - The European Commission’s 2024 Digital Decade e Health Indicator Study found EU average access to EHRs via online portals rose to 79% in 2023 from 72% in 2022. - The report links market growth to broader use of precision medicine, genomics and multi-omics integration, AI healthcare platforms, predictive and preventive care, and virtual clinical trials. - The report flags patient-specific predictive disease modeling, virtual clinical simulation for treatment planning, multi-source health data integration, longitudinal monitoring and digital twin use in clinical research and drug development as emerging trends. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.

Between the lines: - The market outlook suggests digital twin platforms are gaining credibility as data infrastructure improves in healthcare. - Rising EHR access and the expansion of personalized therapies make it easier to build and use patient-level models. - The strongest commercial opportunity appears to sit where AI, genomics and clinical workflows overlap.

What's next: - The report expects rapid growth to continue through 2030 as healthcare systems adopt more predictive tools. - Wider use in clinical research, drug development and treatment planning could broaden demand beyond care delivery. - Asia-Pacific’s lead position may deepen if current adoption and investment trends continue.

The bottom line: - Patient digital twin platforms are shifting from an emerging healthcare technology to a fast-growing market tied to precision medicine and data-driven care.